PLIANT THERAPEUTICS, INC.
For the period ended Dec 31, 2025. Filed Mar 11, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 11, 2026
PLRX$0.80-1.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets
| December 31,2025 | December 31,2024 | |
|---|---|---|
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $45,445 | $71,188 |
| Short-term investments | 145,499 | 284,536 |
| Prepaid expenses and other current assets (Note 5) | 4,464 | 6,540 |
| Property and equipment held for sale (Note 4) | 1,040 | — |
| Total current assets | 196,448 | 362,264 |
| Property and equipment, net (Note 4) | 2,940 | 5,525 |
| Operating lease right-of-use assets | 23,966 | 27,243 |
| Restricted cash | 1,482 | 1,482 |
| Other non-current assets | 392 | 435 |
| Total assets | $225,228 | $396,949 |
| Liabilities and stockholders’ equity | ||
| Current liabilities | ||
| Accounts payable | $480 | $5,960 |
| Accrued research and development | 4,804 | 14,363 |
| Accrued liabilities (Note 6) | 9,634 | 12,353 |
| Lease liabilities, current | 1,447 | 542 |
| Total current liabilities | 16,365 | 33,218 |
| Lease liabilities, non-current | 27,658 | 29,439 |
| Long-term debt (Note 7) | — | 30,211 |
| Total liabilities | 44,023 | 92,868 |
| Commitments and Contingencies (Note 14) | ||
| Stockholders’ equity | ||
| Preferred stock, $0.0001 par value 10,000,000 shares authorized at December 31, 2025 and 2024, none issued or outstanding at December 31, 2025 and 2024 | — | — |
| Common stock, $0.0001 par value; 300,000,000 shares authorized at December 31, 2025 and 2024; and 61,449,290 and 60,860,838 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively; | 6 | 6 |
| Additional paid-in capital | 1,040,610 | 1,013,806 |
| Accumulated deficit | (859,396) | (710,052) |
| Accumulated other comprehensive (loss) gain | (15) | 321 |
| Total stockholders’ equity | 181,205 | 304,081 |
| Total liabilities and stockholders’ equity | $225,228 | $396,949 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.